Science Matters: Glimmers Of Hope For Treating ALS

Data And Developments In ALS Research

Recent clinical data using antisense drugs in neurological diseases are encouraging signs that targeting genetic drivers of ALS with antisense oligonucleotides or other gene-altering drugs could halt progression of several forms of the disease.

Science Matters
Updates In ALS Appear At The Annual Meeting Of The American Academy of Neurology

Much of the buzz at the annual meeting of the American Academy of Neurology (AAN) in early May was around competitive drugs for treating spinal muscular atrophy (SMA), including Biogen Inc.’s Spinraza (nusinersen). Biogen also presented late-breaking interim data from a Phase I/II clinical trial of its antisense amyotrophic lateral sclerosis (ALS) drug candidate tofersen (BIIB067). Only 2% or so of the ALS patient population has a mutation in the superoxide dismutase 1 (SOD1) gene, the target of tofersen. But the tofersen data, coupled with the success of Spinraza, which is also an antisense oligonucleotide (ASO) aimed at a gene mutation affecting neurons, are encouraging signs that targeting genetic drivers of ALS with ASOs or other gene-altering drugs could halt progression of several forms of the disease.

The tofersen data, while preliminary, provided assurance that the drug hits its target and is consistent with the belief that...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Innovation

IMMA Starts A Silent Revolution By Making IVF Journey Digital, Predictable And At Home

 
• By 

IMMA’s transvaginal at-home ovarian stimulation monitoring system using ultrasound and AI image analysis increases the chances of early IVF success. It won the Biomed Israel 2025 IVD start-up showcase award. Further potential applications could follow, cofounder/CEO Beatrice Chemla told In Vivo.

CRL Trio Brings Shifting Sand To Regenerative Medicine Regulation

 

Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.

More from In Vivo

When Simple Is Best: A Pre-Term Birth Device To End The ‘Silent Emergency’

 
• By 

The Lioness non-surgical silicon ring implant is designed to put an end to pre-term births, sparing maternal anguish and saving health system costs. PregnanTech won the Biomed Israel 2025 medtech start-up award, and Limor Sandach told In Vivo how a non-digital technology beat off stiff competition.

Rising leaders 2025: Aneesh Karatt-Vellatt On Maxion Therapeutics’ Antibody Revolution

 
• By 

Aneesh Karatt-Vellatt is leading the charge to redefine how ion channels and G protein-coupled receptors (GPCRs) are targeted with antibody therapies, one of the most notoriously challenging classes of drug targets.

Podcast: Scancell’s Cancer Vaccine Progress With NHS Partnership

 
• By 

In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.